Biology Reference
In-Depth Information
Murga, J. D., Franti, M., Pevear, D. C., Maddon, P. J., and Olson, W. C. (2006). Potent antiviral
synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immuno-
deficiency virus type 1. Antimicrob. Agents Chemother. 50, 3289-3296.
Myers, M. C., Shah, P. P., Beavers, M. P., Napper, A. D., Diamond, S. L., Smith, A. B., 3rd, and
Huryn, D. M. (2008). Design, synthesis, and evaluation of inhibitors of cathepsin L: Exploiting a
unique thiocarbazate chemotype. Bioorg. Med. Chem. Lett. 18, 3646-3651.
Ng, T. I., Mo, H., Pilot-Matias, T., He, Y., Koev, G., Krishnan, P., Mondal, R., Pithawalla, R.,
He, W., Dekhtyar, T., Packer, J., Schurdak, M., et al. (2007). Identification of host genes involved
in hepatitis C virus replication by small interfering RNA technology. Hepatology 45, 1413-1421.
Ochsenbauer-Jambor, C., Miller, D. C., Roberts, C. R., Rhee, S. S., and Hunter, E. (2001).
Palmitoylation of the Rous sarcoma virus transmembrane glycoprotein is required for protein
stability and virus infectivity.
J. Virol. 75, 11544-11554.
Okumura, Y., Takahashi, E., Yano, M., Ohuchi, M., Daidoji, T., Nakaya, T., Bottcher, E.,
Garten, W., Klenk, H. D., and Kido, H. (2010). Novel type II transmembrane serine proteases,
MSPL and TMPRSS13, Proteolytically activate membrane fusion activity of the hemagglutinin of
highly pathogenic avian influenza viruses and induce their multicycle replication.
J. Virol. 84,
5089-5096.
Oldstone, M. B., Lewicki, H., Thomas, D., Tishon, A., Dales, S., Patterson, J., Manchester, M.,
Homann, D., Naniche, D., and Holz, A. (1999). Measles virus infection in a transgenic model:
virus-induced immunosuppression and central nervous system disease.
Cell 98, 629-640.
Oomens, A. G., Bevis, K. P., and Wertz, G. W. (2006). The cytoplasmic tail of the human respiratory
syncytial virus F protein plays critical roles in cellular localization of the F protein and infectious
progeny production.
J. Virol. 80, 10465-10477.
Owens, R. J., Burke, C., and Rose, J. K. (1994). Mutations in the membrane-spanning domain of the
human immunodeficiency virus envelope glycoprotein that affect fusion activity.
J. Virol. 68, 570-574.
Owsianka, A., Tarr, A. W., Juttla, V. S., Lavillette, D., Bartosch, B., Cosset, F. L., Ball, J. K., and
Patel, A. H. (2005). Monoclonal antibody AP33 defines a broadly neutralizing epitope on the
hepatitis C virus E2 envelope glycoprotein. J. Virol. 79, 11095-11104.
Ozden, S., Lucas-Hourani, M., Ceccaldi, P. E., Basak, A., Valentine, M., Benjannet, S., Hamelin, J.,
Jacob, Y., Mamchaoui, K., Mouly, V., Despres, P., Gessain, A., et al. (2008). Inhibition of
Chikungunya virus infection in cultured human muscle cells by furin inhibitors: impairment of
the maturation of the E2 surface glycoprotein. J. Biol. Chem. 283, 21899-21908.
Pager, C. T., and Dutch, R. E. (2005). Cathepsin L is involved in proteolytic processing of the
Hendra virus fusion protein. J. Virol. 79, 12714-12720.
Palermo, C., and Joyce, J. A. (2008). Cysteine cathepsin proteases as pharmacological targets in
cancer. Trends Pharmacol. Sci. 29, 22-28.
Park, P. W., Reizes, O., and Bernfield, M. (2000). Cell surface heparan sulfate proteoglycans:
selective regulators of ligand-receptor encounters.
J. Biol. Chem. 275, 29923-29926.
Parker, J. S., Murphy, W. J., Wang, D., O'Brien, S. J., and Parrish, C. R. (2001). Canine and feline
parvoviruses can use human or feline transferrin receptors to bind, enter, and infect cells.
J. Virol.
75, 3896-3902.
Pecheur, E. I., Lavillette, D., Alcaras, F., Molle, J., Boriskin, Y. S., Roberts, M., Cosset, F. L., and
Polyak, S. J. (2007). Biochemical mechanism of hepatitis C virus inhibition by the broad-
spectrum antiviral arbidol.
Biochemistry 46, 6050-6059.
Pernet, O., Pohl, C., Ainouze, M., Kweder, H., and Buckland, R. (2009). Nipah virus entry can occur
by macropinocytosis.
Virology 395, 298-311.
Perotti, M., Mancini, N., Diotti, R. A., Tarr, A. W., Ball, J. K., Owsianka, A., Adair, R., Patel, A. H.,
Clementi, M., and Burioni, R. (2008). Identification of a broadly cross-reacting and neutralizing
human monoclonal antibody directed against the hepatitis C virus E2 protein.
J. Virol. 82,
1047-1052.
